STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews : A Journal of Immunology Review Article

Post Covid-Sequela: Novel-Inception of DM: A Review

  1. Michael Sanjeev Kumar Department of [Department Name], Bharathiar University, Coimbatore
  2. Viji Michael Sanjeev Kumar Department of Applied Medical Sciences, University of Bisha

Abstract

As patients recovers from COVID 19 pandemic, a subset of the covid patients experienced a post covid condition with long term symptoms, few weeks after their discharge or recovery from the (SARS-CoV-2) infection. Hence, we tried to prove the hypothesis whether diabetes mellites is an afresh possible sequala of covid infection by systematically evaluating the consistently changing glucose level of the post covid patients. The databases PubMed and Google Scholar were searched for this purpose. This review study was done by systematically searching the peer-reviewed literatures on new-onset DM as a post covid condition by analysing articles between January 2020 and January 2022. The articles for review include studies on the patients with lingering clinical signs noted and biochemical alterations showing DM as a sequala of post covid infection a least a month after recovery. Thus, this study confirms that selected number of patients are diagnosed with diabetes as a new-onset disease after recovery from the covid infection. The changes noted in the blood glucose level after covid infection confirms the important of considering DM as post covid diagnostic criteria to give proof based clinical care.

Keywords

References (28)

  1. Metwally AA, Mehta P, Johnson BS, Nagarjuna A, Snyder MP. COVID-19–Induced New-Onset Diabetes: Trends and Technologies. Diabetes. 2021;70(12):2733-2744. doi:10.2337/dbi21-0029
  2. Centers for Disease Control and Prevention (CDC). Post-COVID conditions [Internet]. Atlanta (GA): CDC; 2022 [cited 2026 May 14]. Available from: Post-COVID Conditions
  3. National Health Service (NHS). Long-term effects of coronavirus (long COVID) [Internet]. London: NHS; 2022 [cited 2026 May 14]. Available from: Long COVID Information
  4. World Health Organization (WHO). Coronavirus disease (COVID-19): post COVID-19 condition [Internet]. Geneva: WHO; 2022 [cited 2026 May 14]. Available from: Post COVID-19 Condition
  5. Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021:n1098. doi:10.1136/bmj.n1098
  6. Shrestha DB, Budhathoki P, Raut S, Adhikari S, Ghimire P, Thapaliya S, et al. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World Journal of Virology. 2021;10(5):275-287. doi:10.5501/wjv.v10.i5.275
  7. Muhamad SA, Ugusman A, Kumar J, Skiba D, Hamid AA, Aminuddin A. COVID-19 and Hypertension: The What, the Why, and the How. Frontiers in Physiology. 2021;12. doi:10.3389/fphys.2021.665064
  8. Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nature Metabolism. 2021;3(6):774-785. doi:10.1038/s42255-021-00407-6
  9. American Diabetes Association (ADA). Diagnosis [Internet]. Arlington (VA): ADA; 2022 [cited 2026 May 14]. Available from: Diabetes Diagnosis Information
  10. Centers for Disease Control and Prevention (CDC). Long COVID or post-COVID conditions [Internet]. Atlanta (GA): CDC; 2022 [cited 2026 May 14]. Available from: Long COVID or Post-COVID Conditions
  11. Chen M, Zhu B, Chen D, Hu X, Xu X, Shen WJ, et al. COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: a 6-month prospective study. Endocr Pract. 2021;27(8):834-841. doi:10.1016/j.eprac.2021.04.017.
  12. Nesan GSCQ, Keerthana D, Yamini R, Jain T, Kumar D, Eashwer A, et al. 3-Month Symptom-Based Ambidirectional Follow-up Study Among Recovered COVID-19 Patients from a Tertiary Care Hospital Using Telehealth in Chennai, India. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2021;58. doi:10.1177/00469580211060165
  13. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021:n693. doi:10.1136/bmj.n693
  14. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220-232. doi:10.1016/s0140-6736(20)32656-8
  15. Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: a systematic review and meta-analysis. Prim Care Diabetes. 2022;16(5):591-593. doi:10.1016/j.pcd.2022.06.002.
  16. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clinical Gastroenterology and Hepatology. 2020;18(9):2128-2130.e2. doi:10.1016/j.cgh.2020.04.040
  17. Wu J, Mackie SL, Pujades-Rodriguez M. Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. BMJ Open Diabetes Research & Care. 2020;8(1):e001220. doi:10.1136/bmjdrc-2020-001220
  18. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. European Journal of Clinical Investigation. 2009;39(7):618-625. doi:10.1111/j.1365-2362.2009.02153.x
  19. Shaharuddin SH, Wang V, Santos RS, Gross A, Wang Y, Jawanda H, et al. Deleterious Effects of SARS-CoV-2 Infection on Human Pancreatic Cells. Frontiers in Cellular and Infection Microbiology. 2021;11. doi:10.3389/fcimb.2021.678482
  20. Melvin WJ, Audu CO, Davis FM, Sharma SB, Joshi A, DenDekker A, et al. Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. Proceedings of the National Academy of Sciences. 2021;118(38). doi:10.1073/pnas.2101071118
  21. Catriona C, Paolo P. SARS‐CoV‐2 induced post‐translational protein modifications: A trigger for developing autoimmune diabetes? Diabetes/Metabolism Research and Reviews. 2022;38(1). doi:10.1002/dmrr.3508
  22. Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nature Communications. 2021;12(1). doi:10.1038/s41467-021-23886-3
  23. Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021;2021(8). doi:10.1002/14651858.cd014963
  24. Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, et al. COVID-19 and metabolic disease: mechanisms and clinical management. The Lancet Diabetes & Endocrinology. 2021;9(11):786-798. doi:10.1016/s2213-8587(21)00244-8
  25. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. Scientific Reports. 2017;7(1). doi:10.1038/s41598-017-09536-z
  26. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118-121. doi:10.1038/nature17200
  27. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022;328(7):676. doi:10.1001/jama.2022.11691
  28. Hurissi E, Alameer M, Ageeli F, Allami M, Alharbi M, Suhail H, et al. The Association between SARS-CoV-2 Infection and Diabetic Ketoacidosis in Patients with New-Onset Diabetes: A Retrospective Study from a Diabetic Center in Saudi Arabia. Pediatric Reports. 2022;14(4):519-527. doi:10.3390/pediatric14040060
Support